Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended September 30, 2019

Posted On: 2019-10-22 22:01:47


GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended 30th September 2019. Revenue for the quarter came in at Rs.873 crores with a growth of 8%. Profit After Tax (including exceptional items) at Rs.503 crores recorded a growth of 399%.

Exceptional items recognised in the quarter includes divestment of the company's land at Thane for a net consideration of Rs.552 crores, pursuant to receipt of all statutory and regulatory approvals from the concerned authorities. Exceptional items also include the financial impact of product recall detailed below:

GSK has been contacted by regulatory authorities regarding the detection of NOMA in ranitidine products. Based on the information received and correspondence with regulatory authorities, GSK made the decision to suspend the release, distribution and supply of all dose forms of ranitidine hydrochloride products to all markets, including India, as a precautionary action pending the outcome of ongoing tests and investigations. GSK manufactures Ranitidine Hydrochloride IP Tablets 150 mg and 300 mg (Zinetac) for supply to the Indian market.

Further to additional information received and as a precautionary action, GSK made the decision to initiate a voluntary pharmacy/retail level recall of the Zinetac products above from the Indian market. GSK is continuing with investigations into the potential source of the NOMA. These investigations include continued engagement with our API suppliers. Patient safety remains our utmost priority and we are taking this issue very seriously.

Commenting on the results, A. Vaidheesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said, "Our global Innovation, Performance & Trust (IPT) strategy underpinned by our culture, has guided investment of our resources in focus therapies which is showing encouraging results with our promoted brands recording +20% growth this quarter. We continue to see the annualizing effect of discontinued tailend brands. Adjusting for this our underlying sales growth is 16% supported by strong volume growth of 11%.

We continue to drive improved operational efficiencies reflecting in our EBITOA margin improving by 2 percentage points, to 22%. We have also seen some early success on the launch of Nucala (Mepolizumab) which is a humanised monoclonal antibody and indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.

GSK's consistent commitment to being gender inclusive has been recognised externally. We have been identified among India's Best Workplaces for Women 2019, by the Great Place to Work® Institute and have also, once again, featured as 100 Best Companies for Women in India by Working Mother & Avtar. Both these recognitions are based on feedback from our women colleagues, their engagement and perceptions and also from assessment of our existing policies and processes as benchmarked against the best in the industry."

Shares of GLAXOSMITHKLINE PHARMACEUTICALS LTD. was last trading in BSE at Rs.1469.15 as compared to the previous close of Rs. 1440.15. The total number of shares traded during the day was 17683 in over 1841 trades.

The stock hit an intraday high of Rs. 1505.9 and intraday low of 1430. The net turnover during the day was Rs. 25826734.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Sun Pharmaceutical Industries Ltd Board approves final dividend of Rs. 1 for FY2020

Aditya Birla Fashion and Retail Limited board approves fund raising of Rs. 1000 crore

DABUR India Ltd posts lower consolidated PAT of Rs. 281.17 crore in Q4 FY20

Sun Pharmaceutical Industries Ltd reports Rs. 399.84 crore consolidated PAT in Q4 FY20

KPIT Technologies Ltd consolidated Q4 net profit at Rs. 37.13 crore

Saksoft Ltd consolidated Q4 FY2020 net profit at Rs. 9.79 crore

JSW Holdings Ltd Q4 consolidated PAT up at Rs. 9.60 crore

Beardsell Ltd board approves 1:3 rights issue

Manappuram Finance Ltd approves issue of NCDs of Rs. 500 crore

TCS iON Readies Exam Centers to Operate with Social Distancing and Hygiene Norms Post Lockdown

TIMKEN India Ltd board to approve quarterly results on June 5, 2020

Relaxo Footwears Ltd board to consider FY20 results, final dividend on June 6, 2020

Tamboli Capital Ltd board to announce FY20 results, dividend on June 13, 2020

Indian Oil Corporation Ltd allots NCDs of Rs. 3000 crore

Sagarsoft (India) Ltd board recommends dividend of Rs. 1.50

Zydus Wellness Ltd board to approve Q4, FY20 results on June 2, 2020

Indostar Capital Finance Ltd allots securities to BCP V Multiple Holdings Pte. Ltd

Aurobindo Pharma Ltd board to consider 4th quarter results on June 3, 2020

Adani Ports and Special Economic Zone Limited raises Rs. 700 crores through NCDs

TCS a Leader and Star Performer in Property & Casualty Insurance BPO Services: Everest Group

Future Retail Ltd board approves raising of upto Rs. 650 crore through NCDs

Garden Reach Shipbuilders & Engineers Ltd board to consider FY20 results, final dividend on June 6, 2020

Birla Cable Ltd board to approve Q4, FY20 results on June 1, 2020

Glenmark Pharmaceuticals receives ANDA approval for Chlorzoxazone Tablets USP, 375 mg and 750 mg

L&T Heavy Engineering Achieves Delivery of Critical Equipment to Global Customers During Lockdown

Wipro positioned as a 'Leader' in Gartner's 2020 Magic Quadrant for Public Cloud Infrastructure Professional and Managed Services, Worldwide

Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients

Millers Mutual Selects Majesco's Cloud-Native Digital1st® Insurance Platform

Paisalo Digital Ltd board to consider raising funds through NCDs

Blue Dart Express Sales at Rs. 31,664 million

Sun Pharma Advanced Research Company Ltd board to announce 4th quarter results on June 2, 2020

Stovec Industries Ltd board to consider Q4, FY20 results on June 4, 2020

Greaves Cotton Limited board to approve Q4, FY20 results on June 5, 2020

CRISIL reaffirms commercial papers rating of Edelweiss Financial Services Limited

Gulshan Polyols Ltd Q4 PAT at Rs. 2.78 crore

Alkem Laboratories Ltd Board to consider FY20 results & Final Dividend on June 05, 2020

Wonderla Holidays Ltd Q4 FY20 PAT slides to Rs. 1.56 crore

S H Kelkar and Company Ltd consolidated Q4 FY2020 PAT at Rs. 12.02 crore

Kewal Kiran Clothing Ltd posts Rs. 15.76 crore consolidated PAT in Q4 FY2020

Gujarat Gas Ltd board to consider FY20 results, dividend on June 5, 2020

Kewal Kiran Clothing Ltd Board approves Dividend of Rs. 6

Deepak Nitrite Ltd reports consolidated PAT of Rs. 172.30 crore in Q4 FY2020

Coromandel International Ltd board recommends dividend of Rs. 12 for FY2020

Fiinovation Partners with Dhampur Sugar to help Delhi Slums Fight COVID-19 Pandemic

LTI Wins 2020 SAP® Pinnacle Award as the Industry Innovation Partner of the Year

Kotak Mahindra Bank fixes floor price for QIP as Rs. 1147.75

Wipro launches Global Channel Partner Program for innovative products and platforms

Shanthi Gears Limited announces financial results for period ended March 31, 2020

V I P Industries Ltd reports consolidated Q4 FY20 PAT at Rs. 9.52 crore

Coromandel International Ltd Q4 FY20 consolidated net profit at Rs. 234.20 crore







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019